Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: An overview of emesis PART 06: Market landscape • Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by application • Chemotherapy • Surgery • Gastroenteritis • Others PART 09: Market segmentation by drug class • 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist • Dopamine antagonist • Neurokinin-1 (NK 1) receptor antagonist • Cannabinoid receptor antagonist • Others PART 10: Geographical segmentation • Antiemetic drug market in Americas • Antiemetic drug market in EMEA • Antiemetic drug market in APAC PART 11: Decision framework PART 12: Drivers and challenges • Market drivers • Market challenges PART 13: Market trends • Inorganic growth strategies • Guidelines for CINV drug development • Antiemetic oral soluble films PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • GlaxoSmithKline • Johnson & Johnson • Pfizer • Sanofi • Other prominent vendors PART 16: Appendix • List of abbreviations List of Exhibits  Exhibit 01: Application of antiemetic drugs Exhibit 02: Major antiemetic drug class Exhibit 03: Global antiemetic drugs market snapshot 2016 Exhibit 04: Steps involved in emesis Exhibit 05: Mechanism of emesis Exhibit 06: Causes of emesis Exhibit 07: Global antiemetic drug market snapshot Exhibit 08: Global antiemetic drugs market 2016-2021 ($ millions) Exhibit 09: Opportunity analysis in global antiemetic drugs market Exhibit 10: Five forces analysis Exhibit 11: Pipeline analysis of vendors in Phase I Exhibit 12: Pipeline analysis of vendors in Phase II Exhibit 13: Pipeline analysis of vendors in Phase III Exhibit 14: Key clinical trials Exhibit 15: Market segmentation by application 2016 Exhibit 16: Global antiemetic chemotherapeutic drugs market 2016-2021 ($ millions) Exhibit 17: Global antiemetic surgery treatment market 2016-2021 ($ millions) Exhibit 18: Global antiemetic gastroenteritis drugs market 2016-2021 ($ millions) Exhibit 19: Various emetics symptoms Exhibit 20: Global antiemetic other drugs market 2016-2021 ($ millions) Exhibit 21: Segmentation of global antiemetic drugs market by drug class 2016 Exhibit 22: Other drug classes of antiemetic drugs market Exhibit 23: Segmentation of global antiemetic drugs market by geography 2016 and 2021 Exhibit 24: Segmentation of global antiemetic drugs market revenue by geography 2016-2021 ($ millions) Exhibit 25: Market scenario in Americas Exhibit 26: Antiemetic drugs market in Americas 2016-2021 ($ millions) Exhibit 27: Market scenario in EMEA Exhibit 28: Antiemetic drugs market in EMEA 2016-2021 ($ millions) Exhibit 29: Market scenario in APAC Exhibit 30: Antiemetic drugs market in APAC 2016-2021 ($ millions) Exhibit 31: Factors causing PONV Exhibit 32: Triggers and therapeutics for CINV Exhibit 33: Revenue of Kytril marketed by F. Hoffmann-La Roche 2014-2016 ($ millions) Exhibit 34: Competitive structure analysis of global antiemetic drug market 2016 Exhibit 35: Competitive factors of global antiemetic drugs market Exhibit 36: Market penetration of various global antiemetic drugs manufacturers 2016 Exhibit 37: Strategic success factors of companies in global antiemetic drugs market Exhibit 38: GSK: Key highlights Exhibit 39: GlaxoSmithKline: Strength assessment Exhibit 40: GlaxoSmithKline: Strategy assessment Exhibit 41: GlaxoSmithKline: Opportunity assessment Exhibit 42: Johnson & Johnson: Key highlights Exhibit 43: Johnson & Johnson: Strength assessment Exhibit 44: Johnson & Johnson: Strategy assessment Exhibit 45: Johnson & Johnson: Opportunity assessment Exhibit 46: Pfizer: Key highlights Exhibit 47: Pfizer: Strength assessment Exhibit 48: Pfizer: Strategy assessment Exhibit 49: Pfizer: Opportunity assessment Exhibit 50: Sanofi: Key highlights Exhibit 51: Sanofi: Strength assessment Exhibit 52: Sanofi: Strategy assessment Exhibit 53: Sanofi opportunity assessment

GlaxoSmithKline, Johnson & Johnson, Pfizer, Sanofi, bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.